Edward F Patz1, Erin Greco2, Constantine Gatsonis3, Paul Pinsky4, Barnett S Kramer4, Denise R Aberle5. 1. Department of Radiology, and Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA. Electronic address: patz0002@mc.duke.edu. 2. Center for Statistical Sciences, Brown University School of Public Health, Providence, RI, USA. 3. Center for Statistical Sciences, Brown University School of Public Health, Providence, RI, USA; Department of Biostatistics, Brown University School of Public Health, Providence, RI, USA. 4. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA. 5. Department of Radiology, UCLA, Los Angeles, CA, USA.
Abstract
BACKGROUND: Annual low-dose CT screening for lung cancer has been recommended for high-risk individuals, but the necessity of yearly low-dose CT in all eligible individuals is uncertain. This study examined rates of lung cancer in National Lung Screening Trial (NLST) participants who had a negative prevalence (initial) low-dose CT screen to explore whether less frequent screening could be justified in some lower-risk subpopulations. METHODS: We did a retrospective cohort analysis of data from the NLST, a randomised, multicentre screening trial comparing three annual low-dose CT assessments with three annual chest radiographs for the early detection of lung cancer in high-risk, eligible individuals (aged 55-74 years with at least a 30 pack-year history of cigarette smoking, and, if a former smoker, had quit within the past 15 years), recruited from US medical centres between Aug 5, 2002, and April 26, 2004. Participants were followed up for up to 5 years after their last annual screen. For the purposes of this analysis, our cohort consisted of all NLST participants who had received a low-dose CT prevalence (T0) screen. We determined the frequency, stage, histology, study year of diagnosis, and incidence of lung cancer, as well as overall and lung cancer-specific mortality, and whether lung cancers were detected as a result of screening or within 1 year of a negative screen. We also estimated the effect on mortality if the first annual (T1) screen in participants with a negative T0 screen had not been done. The NLST is registered with ClinicalTrials.gov, number NCT00047385. FINDINGS: Our cohort consisted of 26 231 participants assigned to the low-dose CT screening group who had undergone their T0 screen. The 19 066 participants with a negative T0 screen had a lower incidence of lung cancer than did all 26 231 T0-screened participants (371·88 [95% CI 337·97-408·26] per 100 000 person-years vs 661·23 [622·07-702·21]) and had lower lung cancer-related mortality (185·82 [95% CI 162·17-211·93] per 100 000 person-years vs 277·20 [252·28-303·90]). The yield of lung cancer at the T1 screen among participants with a negative T0 screen was 0·34% (62 screen-detected cancers out of 18 121 screened participants), compared with a yield at the T0 screen among all T0-screened participants of 1·0% (267 of 26 231). We estimated that if the T1 screen had not been done in the T0 negative group, at most, an additional 28 participants in the T0 negative group would have died from lung cancer (a rise in mortality from 185·82 [95% CI 162·17-211·93] per 100 000 person-years to 212·14 [186·80-239·96]) over the course of the trial. INTERPRETATION: Participants with a negative low-dose CT prevalence screen had a lower incidence of lung cancer and lung cancer-specific mortality than did all participants who underwent a prevalence screen. Because overly frequent screening has associated harms, increasing the interval between screens in participants with a negative low-dose CT prevalence screen might be warranted. FUNDING: None.
BACKGROUND: Annual low-dose CT screening for lung cancer has been recommended for high-risk individuals, but the necessity of yearly low-dose CT in all eligible individuals is uncertain. This study examined rates of lung cancer in National Lung Screening Trial (NLST) participants who had a negative prevalence (initial) low-dose CT screen to explore whether less frequent screening could be justified in some lower-risk subpopulations. METHODS: We did a retrospective cohort analysis of data from the NLST, a randomised, multicentre screening trial comparing three annual low-dose CT assessments with three annual chest radiographs for the early detection of lung cancer in high-risk, eligible individuals (aged 55-74 years with at least a 30 pack-year history of cigarette smoking, and, if a former smoker, had quit within the past 15 years), recruited from US medical centres between Aug 5, 2002, and April 26, 2004. Participants were followed up for up to 5 years after their last annual screen. For the purposes of this analysis, our cohort consisted of all NLST participants who had received a low-dose CT prevalence (T0) screen. We determined the frequency, stage, histology, study year of diagnosis, and incidence of lung cancer, as well as overall and lung cancer-specific mortality, and whether lung cancers were detected as a result of screening or within 1 year of a negative screen. We also estimated the effect on mortality if the first annual (T1) screen in participants with a negative T0 screen had not been done. The NLST is registered with ClinicalTrials.gov, number NCT00047385. FINDINGS: Our cohort consisted of 26 231 participants assigned to the low-dose CT screening group who had undergone their T0 screen. The 19 066 participants with a negative T0 screen had a lower incidence of lung cancer than did all 26 231 T0-screened participants (371·88 [95% CI 337·97-408·26] per 100 000 person-years vs 661·23 [622·07-702·21]) and had lower lung cancer-related mortality (185·82 [95% CI 162·17-211·93] per 100 000 person-years vs 277·20 [252·28-303·90]). The yield of lung cancer at the T1 screen among participants with a negative T0 screen was 0·34% (62 screen-detected cancers out of 18 121 screened participants), compared with a yield at the T0 screen among all T0-screened participants of 1·0% (267 of 26 231). We estimated that if the T1 screen had not been done in the T0 negative group, at most, an additional 28 participants in the T0 negative group would have died from lung cancer (a rise in mortality from 185·82 [95% CI 162·17-211·93] per 100 000 person-years to 212·14 [186·80-239·96]) over the course of the trial. INTERPRETATION: Participants with a negative low-dose CT prevalence screen had a lower incidence of lung cancer and lung cancer-specific mortality than did all participants who underwent a prevalence screen. Because overly frequent screening has associated harms, increasing the interval between screens in participants with a negative low-dose CT prevalence screen might be warranted. FUNDING: None.
Authors: Heber MacMahon; John H M Austin; Gordon Gamsu; Christian J Herold; James R Jett; David P Naidich; Edward F Patz; Stephen J Swensen Journal: Radiology Date: 2005-11 Impact factor: 11.105
Authors: Edward F Patz; Michael J Campa; Elizabeth B Gottlin; Priscilla R Trotter; James E Herndon; Don Kafader; Russell P Grant; Marcia Eisenberg Journal: Am J Respir Crit Care Med Date: 2013-08-15 Impact factor: 21.405
Authors: Denise R Aberle; Sarah DeMello; Christine D Berg; William C Black; Brenda Brewer; Timothy R Church; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; Constantine A Gatsonis; David S Gierada; Amanda Jain; Gordon C Jones; Irene Mahon; Pamela M Marcus; Joshua M Rathmell; JoRean Sicks Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Ugo Pastorino; Marta Rossi; Valentina Rosato; Alfonso Marchianò; Nicola Sverzellati; Carlo Morosi; Alessandra Fabbri; Carlotta Galeone; Eva Negri; Gabriella Sozzi; Giuseppe Pelosi; Carlo La Vecchia Journal: Eur J Cancer Prev Date: 2012-05 Impact factor: 2.497
Authors: William C Black; Ilana F Gareen; Samir S Soneji; JoRean D Sicks; Emmett B Keeler; Denise R Aberle; Arash Naeim; Timothy R Church; Gerard A Silvestri; Jeremy Gorelick; Constantine Gatsonis Journal: N Engl J Med Date: 2014-11-06 Impact factor: 91.245
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; Jonathan D Clapp; Kathy L Clingan; Ilana F Gareen; David A Lynch; Pamela M Marcus; Paul F Pinsky Journal: J Natl Cancer Inst Date: 2010-11-22 Impact factor: 13.506
Authors: Martin C Tammemägi; Timothy R Church; William G Hocking; Gerard A Silvestri; Paul A Kvale; Thomas L Riley; John Commins; Christine D Berg Journal: PLoS Med Date: 2014-12-02 Impact factor: 11.069
Authors: Hilary A Robbins; Christine D Berg; Li C Cheung; Anil K Chaturvedi; Hormuzd A Katki Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506